

PRO-C6-Rec

An endogenous collagen biomarker for unique characterization of kidney transplant recipients



Coordinator

Nordic Bioscience A/S
Denmark

Hospices Civils de Lyon Investigator



Pr. Olivier THAUNAT
Hôpital Edouard Herriot
Service de transplantation,
néphrologie et immunologie
clinique



Total Budget

799,302.95€

Hospices Civils de Lyon Budget

169,889.25 €



The goal of the PRO-C6-Rec project is to develop a disruptive in vitro diagnostic device (IVD) that will guide the allocation of a scarce pool of donor kidney grafts to suitable recipients.

The project will generate a CE marked non-invasive IVD measuring type VI collagen formation, called the PRO-C6 Test.

The PRO-C6 Test characterizes the kidney transplant recipient. More precisely, the assay evaluates his ability to form type VI collagen: the fibrotic tissue that will ultimately destroy the graft. There is an urgent need for improved characterization of kidney transplant recipients as neither clinical parameters nor biomarkers are currently available to accurately predict immediate and long-term kidney function after transplantation.

The PRO-C6-Rec project will determine whether the PRO-C6 Test, currently used in the market of chronic kidney disease patients, can be used in the new market of kidney transplant recipients. The CE marked PRO-C6 Test produced in this project will ensure the highest benefit of kidney transplantation for the individual patient as well as for the community (optimisation of the allocation of scarce graft resource).

The participation of the HCL to the European PRO-C6-Rec project, has been made possible thanks to the biocollection established by the Service de Transplantation Néphrologie et Immunologie Clinique of Edouard Herriot hospital within the frame of **CENTAURE foundation** and Lyon Immunopathology Federation (**LIFe**).

Timeline of the project

1st May 2019

36 months

4 beneficiaries

30st April 2022